#MOCA TEST SCORING RATIO OR INTERVAL SKIN#

#MOCA TEST SCORING RATIO OR INTERVAL SKIN#

The remaining 20% (100/505) of deaths occurred due to other causes, including peripheral vascular disease, other respiratory disease, other diseases in the nervous system and the sense organs, infectious/parasitic disease, disease in the digestive system, disease in skin and subcutaneous tissues, disease in musculoskeletal/connective tissues, mental and behavioral disorder, and benign neoplasms. PD was identified as the underlying cause of death for 41% (206/505), 11% (54/505) of deaths were attributable to neoplasms, 9% (44/505) were due to pneumonia, 5% (27/505) were due to cardiovascular diseases, 5% (25/505) were due to cerebrovascular diseases, 5% (26/505) were due to external causes of morbidity and mortality (including 3 participants who had completed suicide), 3% (17/505) were due to dementia, and 1% (6/505) were due to genitourinary system infections. Death certificates were available for 86% (505/587) of the participants. The SMR was slightly higher in females 2.57 (95% CI: 2.30–2.86) than in males 2.12 (95% CI: 1.95–2.31), but the difference was not statistically significant ( Table 4). Mortality in the PD cohort with an AAO of 20–39 years was more than five times higher than expected, given the mortality in the whole population, with an SMR of 5.55 (95% CI: 3.38–8.61) ( Table 4). Mortality in the PD cohort was more than two times higher than expected, given the mortality in the whole population, with an SMR of 2.28 (95% CI: 2.13–2.44) ( Table 4). Early-onset PD (EOPD) patients (AAO 26 with the same disease duration. Median survival was 15 years (95% CI: 14.2–15.5) for the whole cohort.

Survival curves were estimated using the standard Kaplan-Meier estimator, and multivariable Cox proportional hazard models were estimated to investigate associations. Comparisons to the Norwegian population were performed by calculating standardized mortality ratios (SMRs). By the end of January 2020, 587 patients had died. The cohort was followed longitudinally from 1997. This study compared mortality in the Trondheim PD cohort to the general population, investigated causes of death and analyzed the associations between mortality and age at disease onset (AAO) and cognitive decline defined as Montreal Cognitive Assessment (MoCA) score below 26. Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to the date of death.

Moca test scoring ratio or interval